Summary Background Data
Graft patency may give an unrealistic impression of the outcome of bypass surgery.
Methods
During a 6-year period, 236 patients undergoing primary vein grafts were entered into the study. An ideal outcome required the patient to have survived 12 months with a patent graft on duplex scanning, no perioperative complication, and no further related open or endovascular surgery or admission.
Results
At 12 months, the secondary graft patency rate was 82%; however, only 22% of patients had an ideal outcome. At 1 year, 44 (19%) patients died, 93 (39%) required further ipsilateral and 39 (17%) contralateral intervention, and a total of 108 (46%) were readmitted. An ideal outcome was more likely in patients receiving calcium channel blockers, principally because of improved primary patency, and less likely in those with cardiac failure requiring furosemide, principally because of worse survival in these patients.
Conclusions
Few patients achieve an ideal result after infrainguinal vein bypass. Outcome may be improved by the use of calcium channel blockers. Careful consideration is required before performing revascularization in patients with cardiac failure.
Vein bypass is accepted as an appropriate intervention in most patients with critical ischemia, 1 but infrainguinal revascularization can be the beginning of a series of hospital admissions and operations aimed at maintaining graft function, limb salvage, or ambulation. 2 For example, the acceptance by many of the value of identifying graft stenosis and carrying out prompt corrective surgery leads to many patients undergoing further surgery. 2, 3 The outcome of bypass surgery is traditionally reported in terms of patency (i.e., the percentage of grafts free from occlusion), 4 but this may give little information regarding the patient's quality of life after surgery. 5 Perioperative complications, repeated admissions to the hospital, and particularly further surgery all interfere with recovery from bypass surgery. The aim of this study was to assess the outcome of infrainguinal vein bypass in terms of the freedom from further surgery, hospital admission, and complications.
METHODS

Patients and Surgical Technique
All patients undergoing infrainguinal vein bypass between August 1993 and 1999 were included in the study. Patients were entered into the study based on one limb; if further procedures were subsequently required in the other lower limb, these were recorded as contralateral procedures. No patients were excluded from the study. A total of 236 patients underwent infrainguinal vein bypass for popliteal aneurysm (n ϭ 5), disabling intermittent claudication (n ϭ 92), rest pain (n ϭ 48), ischemic ulceration (n ϭ 53), gangrene (n ϭ 23), or acute ischemia (n ϭ 15). For the purposes of this report, rest pain, ischemic ulceration, gangrene, and acute ischemia were defined as critical ischemia. The operation was performed or supervised by one of four vascular consultants. Most operations were performed with reversed vein (n ϭ 207), with the in situ technique used in 29 patients. The vein was harvested with minimal handling, using skin bridges where possible, and heparinized saline was used to distend the vein and identify open side branches. Intravenous heparin was given routinely before arterial control and was not reversed at the end of the procedure. The distal anastomosis was to the above-knee popliteal artery (n ϭ 103), the below-knee popliteal artery (n ϭ 79), or a tibial artery (n ϭ 54). The vein graft was placed subcutaneously to aid orientation. A completion angiogram was obtained in all patients.
All patients were prescribed 5,000 units subcutaneous heparin twice daily while in the hospital. Most patients were given aspirin at the time of surgery and on discharge. Patients already receiving warfarin (mostly for atrial fibrillation) continued this medication in place of aspirin. If the patient had previous side effects from aspirin or similar agents or refused to take this medication, no antiplatelet agent or anticoagulant was prescribed.
If graft occlusion was discovered within 24 hours of surgery, surgical thrombectomy or graft revision was undertaken if the patient was medically fit and willing to undergo further surgery. If graft occlusion was evident after discharge and was likely to have occurred days or weeks earlier, repeat bypass surgery was considered based on the severity of the limb ischemia, the patient's medical comorbidities, the likelihood of success, and the patient's wishes.
Data Collection
Clinical data (age, gender, presenting complaint, comorbidity, perioperative and discharge medication), angiographic run-off data (number of tibial vessels patent and in continuity from level of distal anastomosis to ankle), and surgical data (graft type, level of anastomosis) were collected prospectively and entered onto a database (Microsoft Visual FoxPro 6.0; Microsoft, Redmond, WA).
Duplex Surveillance and Follow-Up
Duplex scanning of the vein graft was performed before discharge, at 3, 6, and 12 months, and then yearly. Clinical assessment was carried out during the visit for ultrasound. Seventeen (7%) of the patients entered into this study had incompressible ankle arteries, and the ankle-brachial pressure index was not routinely performed on patients during follow-up. Graft revision was considered for stenoses of 70% or more (velocity ratio Ն3.5). Primary and secondary patency was defined in line with the recommendations for reporting the outcome of infrainguinal bypass. 4 Because there is no universally accepted disease-specific quality of life measure for patients undergoing infrainguinal bypass,
Data Analysis
Perioperative and follow-up data were transferred to a statistical package (StatView; Abacus Concepts, Berkeley, CA) for further analysis. Univariate (chi-square) and multiple logistic regression analyses were carried out to assess determinants of outcome at 12 months. Patients who died before 12 months (n ϭ 44) were excluded from the analysis of determinants of graft patency unless graft failure had occurred before death (n ϭ 13).
RESULTS
Outcome Within 30 Days
Twenty-four grafts (10%) became occluded in the immediate perioperative period: six patients underwent successful repeat bypass surgery and eight patients eventually required major amputation (five below-knee, three above-knee; two presented with intermittent claudication), eight patients have not required amputation after conservative treatment (three presented with intermittent claudication), and two patients died within 6 months. By univariate analysis early graft occlusion was more common in patients with critical ischemia (18/137) compared with those with intermittent claudication (6/99, P ϭ .04), those with poor run-off (15/ 134 patients with zero or one patent run-off arteries vs. 9/102 with two or three patent run-off arteries, P ϭ .05), and those not receiving calcium channel blockers (22/180 not receiving calcium channel blockers vs. 2/56 receiving these drugs, P ϭ .04). Other factors, such as anticoagulant or antiplatelet medication, were not predictive of early graft patency.
Thirty-four patients (14%) required reoperation of the ipsilateral leg within 30 days of surgery for bleeding (n ϭ 13), debridement of necrotic tissue (n ϭ 9), revision of occluded graft (n ϭ 9), or wound revision (n ϭ 3). Other complications included cardiac failure, arrhythmia, or infarction (n ϭ 11), renal impairment (n ϭ 4), pneumonia (n ϭ 2), stroke (n ϭ 1) wound infection (n ϭ 13), hematoma (n ϭ 14), and lymph leak (n ϭ 10).
Outcome at 12 Months
At 1 year, 126 patients were alive with patent grafts that had not been revised, 40 patients had undergone successful graft revision for stenosis (n ϭ 20) or occlusion (n ϭ 20), 39 patients had uncorrected graft occlusion, and 31 patients had died with patent grafts. Thirteen of the patients with failed grafts had also died by 12 months. On Kaplan-Meier analysis, primary and secondary patency rates were 63% Ϯ 3% and 82% Ϯ 2% at 12 months and 60% Ϯ 3% and 81% Ϯ 2% at 24 months, respectively. By univariate analysis, graft failure (loss of primary patency) within 12 months was predicted by not receiving aspirin (P ϭ .0004) or calcium channel blockers (P ϭ .04), being prescribed digoxin (P ϭ .01), presenting with critical ischemia (P ϭ .01), and having poor tibial run-off (P ϭ .01). On multiple logistic regression analysis, primary patency was more likely for patients receiving aspirin or calcium channel blockers (Table 1) . Of the 83 patients not taking aspirin, 50 were prescribed warfarin and 33 were receiving no antiplatelet agent or oral anticoagulant. Figure 1 illustrates the effect of aspirin and calcium channel blockers and tibial run-off on primary patency up to 24 months. Only 34 patients were receiving both aspirin and calcium channel blockers. Multiple logistic regression showed no advantage in terms of primary patency of receiving both drugs, although because of the small numbers the confidence intervals were large (odds ratio 2.3, 95% confidence intervals 0.5-11).
A total of 44 patients (19%) died within 12 months of surgery. By Kaplan-Meier analysis, the survival rates were 81% Ϯ 2% at 12 months and 75% Ϯ 3% at 24 months. Death was predicted by numerous factors on univariate analysis, but only critical ischemia (P ϭ .007) and being prescribed furosemide (P ϭ .02) were predictive on multivariate analysis. The effect of critical ischemia and furosemide on survival is shown in Figure 2 . By 12 months, 13 patients required major amputation (2 presenting with intermittent claudication and 11 presenting with rest pain or tissue loss, P ϭ .01). For the 137 patients with critical ischemia, the limb salvage rate was 91% Ϯ 2% at 12 and 24 months.
By Kaplan-Meier analysis, at 12 months 42% of patients required further related open or endoluminal surgery on the ipsilateral leg, whereas 18% of patients had undergone surgical or endovascular revascularization of the contralateral leg. Sixty-one of the 93 patients (66%) requiring repeat surgery on the ipsilateral leg had a graft patency problem (i.e., the graft had occluded or was stenosed). Only 48% of patients were free of further surgery on either leg at 12 months, with only 115 patients (49%) surviving to 1 year after their original surgery without either a perioperative complication or further surgery on the ipsilateral leg. One hundred eight (46%) patients were readmitted for related problems within 1 year of their original surgery, with the median number of readmissions being 1 (range 1-6).
The ideal result of a functioning graft, no perioperative complication or readmission, no further surgery on either leg, and survival to 12 months was achieved in 52 patients (22%). A good result was achieved in 73 (31%) patients, 40 of those presenting with intermittent claudication and 33 who had critical ischemia (P ϭ .007). A fair result was achieved in 102 (43%) patients. An ideal outcome was more common in patients receiving calcium channel blockers but less likely in patients with cardiac failure requiring furosemide (Table 2) .
DISCUSSION
A successful infrainguinal bypass would ideally involve an uncomplicated hospital admission with durable limb salvage and improvement in walking ability. Unfortunately, this is rarely achieved. Despite respectable secondary patency and limb salvage rates, an ideal result of a functioning graft without further surgery, complication, or readmission was achieved in only 22% of patients at 1 year. As might be expected with a policy of graft surveillance and reintervention, 6 almost 70% of the revision procedures on the operated improving graft outcome; however, there is no consensus on the most appropriate therapy. 7 Problems in assessing the effects of any drug on the outcome of surgery include the effect of other concurrent medications, the difficulty in measuring compliance, and the fact that drug prescribing is influenced by the clinician's concern regarding the expected graft outcome.
Our finding of an improved outcome for patients receiving calcium channel blockers is interesting. Patients were being prescribed this medication before bypass surgery for the treatment of hypertension. Thus, it is possible that the better outcome in these patients relates to another feature in these patients and is not a direct result of this medication. In vitro work has shown a calcium-dependent reduction in the luminal concentration of the anticoagulant protein thrombomodulin in response to arterial flow in a model of human vein bypass. 8 Modulation of this rapid loss of anticoagulant activity in patients taking calcium channel blockers could explain the significant improvement in early graft outcome in this group. However, a randomized trial of these drugs in patients undergoing infrainguinal vein bypass would be required to resolve this issue. A randomized trial of patients at high risk of restenosis after coronary angioplasty showed a beneficial effect of the calcium channel blocker verapamil. 9 The poor outcome of patients receiving furosemide principally relates to the high death rate in this group: 34% at 12 months. The association between furosemide and poor survival is likely to reflect the prescription of this drug for cardiac failure. Digoxin, which is principally prescribed for atrial fibrillation, not left ventricular failure, was not associated with poor outcome (see Table 1 ).
In conclusion, despite repeated reports of favorable secondary patency of infrainguinal vein bypass, there is plenty of scope for improving outcome. Our analysis suggests a beneficial effect for calcium channel blockers in improving outcome. Odds ratios were calculated used multiple logistic regression analysis. Ideal result was defined as a patent graft, no perioperative complications, no further intervention or ipsilateral or contralateral leg, no related readmission, and alive at 12 months.
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